Course Information

PROVIDER STATEMENT

Provided by Integrity CE, LLC and Tumor Board Tuesday.

DISCLOSURE OF COMMMERCIAL SUPPORT

Supported by educational grants from Ferring Pharmaceuticals, Inc, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

MODERATOR

Michael J. Pishvaian, MD, PhD
Associate Professor, Department of Oncology
Director of the Gastrointestinal, Development Therapeutics, and Clinical Research Programs at the NCR
Kimmel Cancer Center at Sibley Memorial Hospital
Johns Hopkins University School of Medicine
Washington, District of Columbia

SCHEDULE

#TumorBoardTuesday takes place on Tuesdays at 8:00 PM Eastern Time.

Date	Topic	Faculty	Disclosures
Tuesday, March 24, 2026	Perioperative Treatment of MIBC in an Evolving Landscape AMA credit	Petros Grivas MD, PhD, FASCO Professor, Department of Medicine, Division of Hematology Oncology University of Washington Medical Director, International Program and Local/Regional Outreach Fred Hutch Cancer Center Seattle, Washington Karine Tawagi, MD Assistant Professor of Medicine Program Director, Hematology/Oncology Fellowship GU Medical Oncologist University of Illinois, Chicago Chicago, Illinois	Petros Grivas MD, PhD, FASCO Consultant: Abbvie, Agenus, ALX, Bayer, Beigene, Exact Sciences, Exelixis, Incyte, Merck, Pfizer, Summit, Taiho, Tempus Research Grant: Incyte, Pfizer Research Grant to Institution: Array, Biomea, BMS, Genentech, Merck, Seagen, Syndax Karine Tawagi, MD Consulting: AstraZeneca, Pfizer, Stemlife Therapeutics* Honoraria: GU Oncology Now, OncLive Research Funding (paid to institution): Lilly Speaker's Bureau: AstraZeneca *This relationship has ended within the past 24 months.
Tuesday, January 13, 2026	PSMA-Targeted Radioligand Therapy for Prostate Cancer AMA credit	Andrew J Armstrong, MD, ScM, FACP Professor of Medicine, Surgery, Pharmacology and Cancer Biology Director of Research Duke Cancer Institute, Center for Prostate and Urologic Cancers Division of Medical Oncology, Departments of Medicine and Urology Duke University School of Medicine Durham, North Carolina Hannah McManus, MD Assistant Professor of Medicine Duke Cancer Institute, Center for Prostate and Urologic Cancers Duke University School of Medicine Durham, North Carolina	Andrew J Armstrong, MD, ScM, FACP Advisory Role: Amgen, Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Janssen, Merck, Novartis, Pfizer Consulting Role: Amgen, Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Janssen, Merck, Novartis, Pfizer Hannah McManus, MD Advisory Role: Astellas, Bayer, Johnson and Johnson, Pfizer* *These relationships have ended within the past 24 months.
Tuesday, November 25, 2025	Intravesical Therapy for High-Risk, BCG-Unresponsive NMIBC AMA credit	Ashish Kamat, MD Professor of Urologic Oncology MD Anderson Cancer Center Houston, Texas Sagar Patel, MD Urologic Oncology Fellow MD Anderson Cancer Center Houston, Texas	Ashish Kamat, MD Advisory Boards/Consulting fees: Astellas Pharma, Atonco Pharma, Biological Dynamics, Bristol Myers Squibb, Carisma, CG Oncology, Cystotech, Eisai, EnGene, Ferring, Genentech, Imagin Medical, ImmunityBio, Imvax, Incyte, Janssen, Medac, Merck, Nonagen Bioscience, Pfizer, Photocure, Protara Therapeutics, Roche, Seagen, Theralase, Urogen Pharma, US Biotest, Valar Labs, Vivet Therapeutics Grants or Contracts: Arquer Diagnostics, EnGene, Ferring, PCORI, Photocure, Seagen, SWOG Leadership or fiduciary role in other board, society, committee, or advocacy group: American Urological Association, European Urology Oncology, International Bladder Cancer Group, Journal of Urology, UroToday, World Bladder Cancer Patient Coalition Patents: CyPRIT Sagar Patel, MD does not have any financial relationships or relationships to products or devices with ineligible companies.
Tuesday, September 9, 2025	Frontline Strategies for Resectable MIBC AMA credit	Guru P. Sonpavde, MD Director of Phase I Clinical Research & Genitourinary Medical Oncology Christopher K. Glanz Chair for Cancer Research AdventHealth Cancer Institute Professor of Medicine, University of Central Florida Orlando, Florida Jonathan Anker, MD, PhD Instructor of Medicine Department of Hematology & Medical Oncology Icahn School of Medicine at Mount Sinai New York, New York	Guru P. Sonpavde, MD Advisory Boards: Astellas, Atkis, Bicycle Therapeutics, Bristol Myers Squibb, Daiichi Sankyo, EMD Serono, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Loxo Oncology, Merck, Pfizer, Scholar Rock, Seattle Genetics, Vial Board Member: Nextbridge Biosciences (unpaid) Consultant/Scientific Advisory Board (SAB)/Trial Steering Committee: Ellipses, Merck, Servier, Syapse Research Support (to institution): Bayer, Blue Earth Diagnostics, EMD Serono, Exelixis, Jazz Therapeutics, Sumitomo Pharma Speaker: Astellas, AstraZeneca, Aveo, Bayer, Exelixis, Gilead, Janssen, Merck, Natera, Pfizer, Seagen Spouse Employment: Exact Sciences, Myriad Travel: Astellas, Bristol Myers Squibb Writing/Educational Fees: DAVA Oncology, Onviv, Practice Update, PrecisCa, UpToDate Jonathan Anker, MD, PhD does not have any financial relationships or relationships to products or devices with ineligible companies.
Tuesday, June 24, 2025	Targeting HIF-2α in ccRCC AMA credit	Brian Rini, MD, FASCO Professor of Medicine Vanderbilt University Medical Center Nashville, Tennessee Paulo Siqueira do Amaral, MD Genitourinary Oncology Clinical Fellow Vanderbilt University Medical Center Nashville, Tennessee	Brian Rini, MD, FASCO Consultant: Arcus, Merck Paulo Siqueira do Amaral, MD does not have any financial relationships or relationships to products or devices with ineligible companies.
Tuesday, May 6, 2025	Targeting FGFR3 in NMIBC AMA credit	Yüksel Ürün, MD Professor of Medicine Department of Medical Oncology Ankara University School of Medicine Ankara, Turkey Emre Yekeduz, MD Research Fellow Department of Genitourinary Oncology Dana Farber Cancer Institute, Harvard Medical School Boston, Massachusetts	Yüksel Ürün, MD Consultant: Astellas, AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline Pharmaceuticals, Janssen, Merck, MSD, Pfizer Emre Yekeduz, MD does not have any financial relationships or relationships to products or devices with ineligible companies.

Stay tuned for upcoming conversations!

PROGRAM OVERVIEW

Oncologists and other clinicians who treat patients with genitourinary (GU) cancers have generally adopted molecular profiling technologies offering insight into the molecular underpinning of renal cell carcinoma, prostate, bladder and other GU-related cancers. Considering the challenges of managing these tumor types, understanding these molecular alterations is critical to incorporating newly approved and emerging targeted agents, including immunotherapies. Yet, translating these findings into clinical applications can be challenging. Determining which potential biomarkers and/or druggable mutations in GU cancers that benefit patients is instrumental in improving patient outcomes. Oncologists and urologists need greater understanding and insight into the foundational genomic discoveries that underly the use of targeted entities.

Tumor Board Tuesday is a regularly scheduled, Twitter-based case discussion forum led by expert faculty modeled on the traditional tumor board presentation. Cases are based on realistic scenarios and supporting data is included for optimal treatment selection and patient management.

Learning Objectives

TARGET AUDIENCE

This educational activity has been designed to meet the needs of medical, surgical, and radiation oncologists, urologists, physician assistants, nurse practitioners, nurses, and other healthcare providers involved in the treatment of genitourinary cancers.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants will be able to:

Integrate genomic, immunogenic, and proteomic aberration assessments to guide treatment decisions
Select personalized therapeutic regimens consistent with current evidence and best practices
Implement supportive care strategies to mitigate and manage unique toxicities associated with recently approved and emerging therapies

Faculty Information and Disclosures

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated. The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Michael L. Pishvaian, MD, PhD
Ad Hoc Advisory Boards: AstraZeneca, Ideaya, Merck, Merus, Seattle Genetics
Educational (Unbranded) Program Speaker: Novartis, Pfizer
Steering Committee: Astellas, Pionyr, Trisalus
Funding to Institution: Amgen, Arcus Bio, Biomed Valley, Boerhinger Ingelheim, Ideaya, Seattle Genetics, Merck, Novartis, Pfizer, RenovoRx, Repare Tx, Tesaro, Tizonia
Stock Ownership: Perthera, Inc.

The Integrity CE, LLC planners and managers and Tumor Board Tuesday patient planners do not have any financial relationships or relationships to products or devices with ineligible companies.

Accreditation Information

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. To receive credit, participants must:

Read the learning objectives and faculty disclosures
Complete the pretest
Study the educational activity
Complete the posttest and the evaluation form

If you wish to claim credit for your participation in TBT conversations from April 1, 2025 – March 31, 2026, you can do so here: https://www.integrityce.com/TBTeval25

ACCREDITATION STATEMENT

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this Other activity (a regularly scheduled social media-based tumor board) for a maximum of 5.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimers and Technical Requirements

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent) Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS Plug-in: Adobe^® Flash^® Player 10

Adobe^® Flash^® Player 10 plug-in should be downloaded
Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below: Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Tumor Board Tuesday 2025: Genitourinary Cancers